We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

47 hedge funds and large institutions have $36.6M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more call options, than puts

Call options by funds: $147K | Put options by funds: $119K

18% less funds holding

Funds holding: 57 → 47 (-10)

29% less capital invested

Capital invested by funds: $51.4M → $36.6M (-$14.9M)

29% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 17

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

Holders
47
Holders Change
-10
Holders Change %
-17.54%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
12
Reduced
17
Closed
11
Calls
$147K
Puts
$119K
Net Calls
+$28K
Net Calls Change
-$293K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$301K
2
CM
CM Management
Florida
+$287K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$262K
4
JAMONY
Jacob Asset Management of New York
California
+$237K
5
TAM
Tocqueville Asset Management
New York
+$173K

Top Sellers

Rank Fund Capital Flow
1
FWM
Frontier Wealth Management
Missouri
-$695K
2
Millennium Management
Millennium Management
New York
-$558K
3
GPCM
Granite Point Capital Management
Massachusetts
-$389K
4
Two Sigma Investments
Two Sigma Investments
New York
-$379K
5
First Trust Advisors
First Trust Advisors
Illinois
-$350K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$9.84M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.93M +$262K +3,425 +5%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$4.51M – – –
SCM
4
Sio Capital Management
New York
$3.27M +$144K +1,887 +4%
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$2.29M – – –
JAMONY
6
Jacob Asset Management of New York
California
$1.47M +$237K +3,100 +18%
Renaissance Technologies
7
Renaissance Technologies
New York
$1.41M -$129K -1,683 -8%
GCP
8
GSA Capital Partners
United Kingdom
$1.27M +$19.2K +251 +1%
PCM
9
Prelude Capital Management
New York
$1.12M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$865K +$22.8K +298 +3%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$646K -$97.1K -1,269 -12%
SCM
12
Stonepine Capital Management
Oregon
$396K +$301K +3,933 +253%
Goldman Sachs
13
Goldman Sachs
New York
$378K -$18.7K -244 -4%
Deutsche Bank
14
Deutsche Bank
Germany
$361K – – –
Bank of New York Mellon
15
Bank of New York Mellon
New York
$315K – – –
Two Sigma Investments
16
Two Sigma Investments
New York
$310K -$379K -4,957 -54%
BlackRock
17
BlackRock
New York
$295K -$20.1K -262 -6%
CM
18
CM Management
Florida
$271K +$287K +3,750 New
E
19
Ergoteles
New York
$269K -$8.04K -105 -3%
TAM
20
Tocqueville Asset Management
New York
$267K +$173K +2,260 +157%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$230K +$91.1K +1,190 +60%
Morgan Stanley
22
Morgan Stanley
New York
$218K -$227K -2,972 -50%
DC
23
Davenport & Co
Virginia
$211K +$5.74K +75 +3%
State Street
24
State Street
Massachusetts
$209K +$131K +1,710 +144%
Northern Trust
25
Northern Trust
Illinois
$198K – – –
1
2 3

NBSE Hedge Fund Activity: Q3 2021 in Review

47 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2021, worth a combined $36.6M — down 29% from $51.4M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NBSE and 1 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 12 added.

The largest buyer was Stonepine Capital Management, adding an estimated $301K. The largest seller was Frontier Wealth Management, exiting entirely with an estimated $695K sold.

  • 47 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2021, down from 57 in Q2 2021.
  • Funds reported $36.6M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2021, down 29% quarter-over-quarter.
  • 1 fund opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -10 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2021 was Stonepine Capital Management, an estimated $301K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2021 was Frontier Wealth Management, an estimated $695K sold.

Based on aggregated 13F filings for Q3 2021.